tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Seres Therapeutics reports Q3 EPS 94c vs ($6.69) last year
PremiumThe FlySeres Therapeutics reports Q3 EPS 94c vs ($6.69) last year
4M ago
MCRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
MCRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
Seres Therapeutics receives award of up to $3.6M from CARB-X
Premium
The Fly
Seres Therapeutics receives award of up to $3.6M from CARB-X
4M ago
Seres Therapeutics’ Earnings Call: Progress Amid Challenges
PremiumCompany AnnouncementsSeres Therapeutics’ Earnings Call: Progress Amid Challenges
7M ago
Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics
Premium
Ratings
Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics
7M ago
Seres Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Seres Therapeutics Reports Q2 2025 Financial Results
7M ago
Seres Therapeutics appoints DesRosier, Thorell as co-CEOs
PremiumThe FlySeres Therapeutics appoints DesRosier, Thorell as co-CEOs
7M ago
Seres Therapeutics presents expanded SER-155 biomarker data at ASCO meeting
Premium
The Fly
Seres Therapeutics presents expanded SER-155 biomarker data at ASCO meeting
9M ago
Buy Rating Maintained for Seres Therapeutics Amid Promising SER-155 Developments and Financial Stability
Premium
Ratings
Buy Rating Maintained for Seres Therapeutics Amid Promising SER-155 Developments and Financial Stability
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100